Efficacious, effective, and embedded interventions: implementation research in infectious disease control
- The Vaccine. Dawood, Richard; Hack, Susan // Conde Nast Traveler;Nov2005, Vol. 40 Issue 11, p88
Discusses medical developments related to the use of vaccines in preventing diseases. History on the use smallpox vaccines; Description of the diseases that can be prevented through immunization; Recommendations for further research on more effective vaccines.
- Does neonatal BCG vaccination protect against tuberculous meningitis? Walker, V.; Selby, G.; Wacogne, I. // Archives of Disease in Childhood;Sep2006, Vol. 91 Issue 9, p789
The article investigates the potential value of neonatal BCG vaccination in protecting children against tuberculosis meningitis by researchers from Birmingham, England. A review of previous studies indicate widely ranging suggestions. A meta-analysis performed in 1993 sought to differentiate...
- Declining Hepatitis A Mortality in the United States during the Era of Hepatitis A Vaccination. Vogt, Tara M.; Wise, Matthew E.; Bell, Beth P.; Finelli, Lyn // Journal of Infectious Diseases;5/1/2008, Vol. 197 Issue 9, p1282
Background. Since the mid-1990s, hepatitis A vaccine has been recommended for US children living in historically high-incidence states and for persons with other risk factors or chronic liver disease (CLD). The incidence of hepatitis A has declined dramatically during the era of vaccination, but...
- WEST NILE A Vaccine on the Way ... But Not This Summer. Carmichael, Mary // Newsweek;6/7/2004, Vol. 143 Issue 23, p14
Offers a look at the development of a vaccine for the West Nile virus. Discussion of the long-term effects of the disease including shortness of breath, fevers, pain, paralysis and irreversible nerve damage; Report on a clinical trial of a vaccine by Acambis.
- Adverse Events Reported Following Live, Cold-Adapted, Intranasal Influenza Vaccine. Izurieta, Hector S.; Haber, Penina; Wise, Robert P.; Iskander, John; Pratt, Douglas; Mink, ChrisAnna; Chang, Soju; Braun, M. Miles; Ball, Robert // JAMA: Journal of the American Medical Association;12/7/2005, Vol. 294 Issue 21, p2720
Context: In June 2003, the US Food and Drug Administration licensed a trivalent live, attenuated influenza vaccine (LAIV-T) for intranasal administration to healthy persons 5 to 49 years of age. Although prelicensure testing involved 20 228 vaccinees, clinical trials were not of sufficient size...
- Modeling Human Papillomavirus Vaccine Effectiveness: Quantifying the Impact of Parameter Uncertainty. Nicolas Van de Velde; Marc Brisson; Marie-Claude Boily // American Journal of Epidemiology;Apr2007, Vol. 165 Issue 7, p762
The development of models is based on assumptions, which inevitably embed a level of uncertainty. Quantifying such uncertainty is particularly important when modeling human papillomavirus (HPV) vaccine effectiveness; the natural history of infection and disease is complex, and age- and...
- VETAID begins vaccination campaign in Somaliland. // Veterinary Record: Journal of the British Veterinary Association;6/14/2008, Vol. 162 Issue 24, p767
The article reports that the Scottish-based international development organization VETAID has begun a mass vaccination campaign in western Somaliland. It mentions that VETAID estimates between 55 to 66 percent of livestock in the area were lost and more than 2000 families have become destitute....
- Updated Recommendations on the Use of Pneumococcal Conjugate Vaccine: Suspension of Recommendation for Third and Fourth Dose. // MMWR: Morbidity & Mortality Weekly Report;3/5/2004, Vol. 53 Issue 8, p177
Presents recommendations on the use of pneumococcal conjugate vaccine (PCV7) for infants in the U.S. Causes of scarcity of the vaccine; Efficacy of the product; Details of the recommendations.
- Vaccination Week of the Americas, April 24--30, 2004. // MMWR: Morbidity & Mortality Weekly Report;4/16/2004, Vol. 53 Issue 14, p310
Announces that the countries in the Americas will participate in the Vaccination Week of the Americas (VWA) from April 24 to 30, 2004. Goals of the VWA; Target group for vaccination; Number of people who will be given vaccines.